Found 1 results
Filters: Author is Z. Zakeri  [Clear All Filters]
M. Hashemi, Moazeni-Roodi, A. K., Fazaeli, A., Sandoughi, M., Taheri, M., Bardestani, G. R., Zakeri, Z., Kordi-Tamandani, D. M., and Ghavami, S., The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis, vol. 9, pp. 1735-1741, 2010.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324. PMid:3358796   Aviram M, Rosenblat M, Bisgaier CL, Newton RS, et al. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590. PMid:9541487 PMCid:508738   Aviram M, Hardak E, Vaya J, Mahmood S, et al. (2000). Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510-2517. PMid:10831526   Baskol G, Demir H, Baskol M, Kilic E, et al. (2005). Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38: 951-955. PMid:16055108   Bauerova K and Bezek A (1999). Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen. Physiol. Biophys. 18 (Spec No.): 15-20.   Blatter MC, James RW, Messmer S, Barja F, et al. (1993). Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879. PMid:8382160   Deighton CM and Walker DJ (1991). The familial nature of rheumatoid arthritis. Ann. Rheum. Dis. 50: 62-65. PMid:1994873 PMCid:1004331   Feingold KR, Memon RA, Moser AH and Grunfeld C (1998). Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307-315.   Gambhir JK, Lali P and Jain AK (1997). Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin. Biochem. 30: 351-355.   Gan KN, Smolen A, Eckerson HW and La Du BN (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19: 100-106. PMid:1673382   Garin MC, James RW, Dussoix P, Blanche H, et al. (1997). Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66. PMid:9011577 PMCid:507768   Griffiths HR and Lunec J (1996). The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett. 388: 161-164.   Halliwell B (1994). Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724.   Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, et al. (2010). Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet. Mol. Res. 9: 333-339. PMid:20198589   Humbert R, Adler DA, Disteche CM, Hassett C, et al. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76. PMid:8098250   Isik A, Koca SS, Ustundag B, Celik H, et al. (2007). Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin. Rheumatol. 26: 342-348. PMid:16642406   Jaswal S, Mehta HC, Sood AK and Kaur J (2003). Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin. Chim. Acta 338: 123-129. PMid:14637276   Leviev I and James RW (2000). Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521. PMid:10669651   Leviev I, Negro F and James RW (1997). Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17: 2935-2939. PMid:9409279   Mackness B, Mackness MI, Arrol S, Turkie W, et al. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423: 57-60.   Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76. PMid:8743898   Maury CP, Junge W and Teppo AM (1984). Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J. Lab. Clin. Med. 104: 761-766. PMid:6092501   McKeown MJ, Hall ND and Corvalan JR (1984). Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin. Exp. Immunol. 56: 607-613. PMid:6744663 PMCid:1536001   Miesel R, Murphy MP and Kroger H (1996). Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic. Res. 25: 161-169. PMid:8885334   Nurcombe HL, Bucknall RC and Edwards SW (1991). Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann. Rheum. Dis. 50: 237-242. PMid:1851410 PMCid:1004393   Popa C, van Tits LJ, Barrera P, Lemmers HL, et al. (2009). Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68: 868-872. PMid:18635596   Primo-Parmo SL, Sorenson RC, Teiber J and La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507. PMid:8661009   Ridderstad A, Abedi-Valugerdi M and Moller E (1991). Cytokines in rheumatoid arthritis. Ann. Med. 23: 219-223. PMid:1930911   Rozenberg O, Rosenblat M, Coleman R, Shih DM, et al. (2003). Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.   Sattar N, McCarey DW, Capell H and McInnes IB (2003). Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963. PMid:14676136   Shih DM, Gu L, Xia YR, Navab M, et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287. PMid:9685159   Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, et al. (2003). Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72: 2877-2885.   Ye S, Dhillon S, Ke X, Collins AR, et al. (2001). An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29: E88. PMid:11522844 PMCid:55900   Zwerina J, Redlich K, Schett G and Smolen JS (2005). Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann. N. Y. Acad. Sci. 1051: 716-729. PMid:16127012